Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Receivables (2024 - 2025)

Tonix Pharmaceuticals Holding has reported Change in Receivables over the past 2 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Change in Receivables at $2.8 million for Q4 2025, up 314.7% from a year ago — trailing twelve months through Dec 2025 was $2.6 million (changed N/A YoY), and the annual figure for FY2025 was $2.6 million, down 28.89%.
  • Change in Receivables for Q4 2025 was $2.8 million at Tonix Pharmaceuticals Holding, up from $1.2 million in the prior quarter.
  • Over the last five years, Change in Receivables for TNXP hit a ceiling of $2.8 million in Q4 2025 and a floor of -$1.3 million in Q4 2024.